سعر Moxitrix 400mg/250ml sol. for inf. 2024

Moxitrix 400mg/250ml sol. for inf. (Arab Co. for Medical Products > Spimaco Misr): Antibiotic (fluoroquinolone) - parenteral.

• Adults (18 years and older): community-acquired pneumonia, uncomplicated and complicated skin and skin-structure infections, complicated intra-abdominal infections; acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis caused by designated susceptible bacteria (boxed warning restricts the last two to patients without alternatives).Population: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (3% or more): nausea, diarrhoea, headache and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to moxifloxacin or any other quinolone antibacterial.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: fluoroquinolones are associated with disabling and potentially irreversible serious reactions (tendinitis and tendon rupture, peripheral neuropathy, CNS effects) and may exacerbate myasthenia gravis (avoid in known myasthenia gravis). Reserve for acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis only when no alternatives exist.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: QT prolongation (avoid with class IA/III antiarrhythmics; caution in hypokalaemia, bradycardia), hypersensitivity and other serious reactions (severe skin reactions, hepatitis, haematological), aortic aneurysm/dissection risk, C. difficile-associated diarrhoea, blood glucose disturbances, photosensitivity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• WarfarinAnticoagulant effect enhanced; monitor prothrombin time/INR and bleeding.DailyMed (U.S. National Library of Medicine)
• Class IA and class III antiarrhythmicsProarrhythmic effect may be enhanced; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Antidiabetic agentsDysglycaemia reported; carefully monitor blood glucose.DailyMed (U.S. National Library of Medicine)

• No human data establish a drug-associated risk; based on animal studies (fetal loss, reduced neonatal weight, skeletal variations at maternally toxic doses) moxifloxacin may cause fetal harm. Advise pregnant women of the potential risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether present in human milk; very low excretion in rat milk. Weigh the benefits of breastfeeding against the mother's need and potential adverse effects on the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Bactericidal; inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes needed for DNA replication, transcription, repair and recombination.